First rolling review of COVID-19 vaccine data underway in Europe

• The European Medicines Agency (EMA) has begun its first rolling review of COVID-19 vaccine data on AstraZeneca (NASDAQ:AZN) and the University of Oxford's candidate AZD1222/ChAdOx1. The review committee will be evaluating the first batch of nonclinical data from lab studies so it is premature to expect a conclusion on safety and effectiveness.
• A rolling review is way of accelerating the process. The FDA uses the same approach for high priority medicines and vaccines.
• Selected tickers: Pfizer (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NASDAQ:MRNA), Sanofi (NASDAQ:SNY), GlaxoSmithKline (NYSE:GSK), Dynavax (NASDAQ:DVAX), Novavax (NASDAQ:NVAX)
• https://seekingalpha.com/news/3618847-first-rolling-review-of-covidminus-19-vaccine-data-underway-in-europe